Several HIV medications are expected to be discontinued by the end of this year, according to a recent communication from the Food and Drug Administration (FDA).

The HIV medications are all manufactured by ViiV Healthcare, a GlaxoSmithKline company. They include:

  • Epzicom (abacavir sulfate, lamivudine): The Company will end distribution of the 600mg/300mg tablet (30 count) on January 1, 2024.
  • Lexiva (fosamprenavir calcium): Both the 700mg tablets (60 count) and the 50mg/mL oral solution (225mL) will no longer be available as of January 1, 2024.
  • Selzentry (maraviroc): Distribution of the 25mg tablet (120 count) and 75mg tablet (120 count) is expected to cease by January 1, 2024. Selzentry 150mg, Selzentry 300mg, and Selzentry Oral Solution will still be available.
  • Tivicay (dolutegravir): The 10mg and 25mg tablets (both 30 count) will no longer be available as of January 1, 2024. Tivicay 50mg tablets and Tivicay PD 5mg will continue to be available.
  • Trizivir (abacavir sulfate, lamivudine, zidovudine): Distribution of the 300mg/150mg/300mg tablet (60 count) is expected to cease on November 27, 2023.
  • Ziagen (abacavir sulfate): The Company will cease distribution of the 300mg tablets (60 count) on January 1, 2024. Ziagen Oral Solution will continue to be available.

Available HIV therapies can be viewed by pharmacological class by accessing our Antiretroviral Formulations clinical chart. Additionally, dosage recommendations for antiretroviral treatments can be compared with our Antiretroviral Treatments clinical chart.

Reference

US Food and Drug Administration. FDA Drug Shortages. Accessed January 4, 2023. https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm.